So, its possible mechanism is shown in Fig. 1, which is through CYP19A1 SNPs, especially through increasing the genotype TT of the rs700518 gene expression, which causes the metabolism level of estrogen to increase, leading to a reduction in the T/E ratio; this triggers IR, raises blood glucose levels, and promotes hyperplasia of prostate gland acinar cells and stromal cells in the prostate tissue, leading to the occurrence of clinical BPH and MetS. The gene discussed is CYP19A1; the disease is benign prostatic hyperplasia.